LLY · Mega Cap · NYSE · Healthcare · Drug Manufacturers - General
Price, momentum, and the numbers behind the story.
Stocksbrew score
77/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Where the analysts and the crowd stand, and what it's worth to know first.
Lowest
$930
Current price
$1,185.77
Median target
$1,385
Highest
$1,600
What it earns and where it earns it, what you're paying for the stock, and the risk sitting on the balance sheet.
ROIC
Strong · Excellent capital returns
42.2%
ROE
Favorable · 107.6% - strong capital efficiency
102.3%
Forward P/E
Needs attention · 47% above avg
28.40x
Price / sales
Rich · Overpriced by revenue
13.24x
Price / FCF
Rich · Expensive vs. cash flow
57.99x
EV / EBITDA
Rich · Earnings can't support price
26.38x
Debt / equity
Needs attention · Unfavorable
1.62x
LLY against the names it's actually compared to.
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $1.11T | 40.2 | +49.6% | 77 | |
| $10.01B | 19.1 | +19.7% | 78 | |
| $32.69B | 34.2 | +15.5% | 78 | |
| $4.23B | 12.7 | +13.5% | 78 | |
| $63.65B | 17.8 | +13.5% | 73 |
Every story that touched the stock this week, newest first.